Skip Navigation
ChemIDplus A TOXNET DATABASE Lite•Browse•Advanced

Substance Name: Zonisamide [USAN:USP:INN:BAN:JAN]
RN: 68291-97-4
UNII: 459384H98V
InChIKey: UBQNRHZMVUUOMG-UHFFFAOYSA-N

Note

  • A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Molecular Formula

  • C8-H8-N2-O3-S

Molecular Weight

  • 212.2282
 

Classification Codes

  • Anticonvulsant
  • Anticonvulsants
  • Antioxidants
  • Calcium Channel Blockers
  • Calcium-Regulating Hormones and Agents
  • Cardiovascular Agents
  • Central Nervous System Agents
  • Drug / Therapeutic Agent
  • Membrane Transport Modulators
  • Protective Agents
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Zonisamide
  • Zonisamide [USAN:USP:INN:BAN:JAN]

MeSH Heading

  • Zonisamide

Synonyms

  • 3-(Sulfamoylmethyl)-1,2-benzisoxazole
  • AD-810
  • BRN 1077076
  • CI-912
  • Exceglan
  • Excegram
  • HSDB 7293
  • PD 110843
  • PD-110843
  • UNII-459384H98V
  • Zonegran
  • Zonisamida
  • Zonisamida [Spanish]
  • Zonisamide
  • Zonisamidum
  • Zonisamidum [Latin]

Systematic Name

  • 1,2-Benzisoxazole-3-methanesulfonamide

Registry Numbers

CAS Registry Number

  • 68291-97-4

FDA UNII

  • 459384H98V

System Generated Number

  • 0068291974

Structure Descriptors

InChI

InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

InChIKey

UBQNRHZMVUUOMG-UHFFFAOYSA-N

Smiles

NS(=O)(=O)Cc1noc2ccccc12

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral 1gm/kg (1000mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987.
monkey LD50 oral > 1gm/kg (1000mg/kg) BEHAVIORAL: ATAXIA

AUTONOMIC NERVOUS SYSTEM: "SMOOTH MUSCLE RELAXANT (MECHANISM UNDEFINED, SPASMOLYTIC)"

GASTROINTESTINAL: NAUSEA OR VOMITING		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987.
mouse LD50 intraperitoneal 699mg/kg (699mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 477, 1980.
mouse LD50 intravenous 816mg/kg (816mg/kg)   Drugs in Japan Vol. -, Pg. 600, 1990.
mouse LD50 oral 1829mg/kg (1829mg/kg)   United States Patent Document. Vol. #4172896,
mouse LD50 subcutaneous 1009mg/kg (1009mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987.
rat LD50 intraperitoneal 733mg/kg (733mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 477, 1980.
rat LD50 intravenous 672mg/kg (672mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987.
rat LD50 oral 1992mg/kg (1992mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987.
rat LD50 subcutaneous 925mg/kg (925mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987.